PGT-A improves IVF success rates by analysing the chromosomes of the embryos, ensuring that all 23 pairs are healthy before transferring to the uterus.
PGT-M can prevent inheritable genetic diseases from being transmitted to the next generation by screening genes for monogenic diseases such as Thalassaemia.
Genesis IVF uses ION TORRENT NGS technology which allows both PGT-A and PGT-M to be done concurrently. Hence, reducing the number of biopsies and risk of damaging your precious embryos.
At Genesis IVF, PGT increases clinical pregnancy rates up to 70%+ as compared to other systems where two biopsies are needed and may reduce the viability, causing possible downgrade to a good embryo/blastocyst.